Antisense oligonucleotide (ASO) therapies represent an alternative therapeutic approach to small molecule kinase inhibitors for targeting LRRK2 in Parkinson's disease. While kinase inhibitors block LRRK2 enzymatic activity, ASOs work by binding to LRRK2 messenger RNA (mRNA) and recruiting RNase H to degrade the transcript, thereby reducing the amount of LRRK2 protein produced by cells[1].
ASO-based approaches offer several potential advantages and challenges compared to kinase inhibitors:
ASOs are short, synthetic single-stranded DNA or RNA sequences (typically 12-25 nucleotides) designed to bind complementary target mRNA sequences through Watson-Crick base pairing. Upon binding, ASOs recruit the enzyme RNase H, which cleaves the RNA strand of the DNA-RNA duplex, leading to mRNA degradation and subsequent reduction in protein production[2].
LRRK2 ASOs are designed to:
The mechanism differs fundamentally from kinase inhibitors:
ASO design focuses on critical regions of the LRRK2 mRNA:
| Target Region | Rationale |
|---|---|
| Coding sequence | Disrupt translation initiation or elongation |
| Splice sites | Alter splicing to create non-functional transcripts |
| 3' UTR | Affect mRNA stability and localization |
BIIB132 is a LRRK2-targeting ASO developed through the Biogen-Ionis collaboration, currently in Phase 1 clinical trials for Parkinson's disease[3].
| Attribute | Value |
|---|---|
| Target | LRRK2 mRNA |
| Company | Biogen / Ionis |
| Chemistry | 2'-O-methoxyethyl (2'-MOE) |
| Route | Intrathecal (spinal) injection |
| Phase | Phase 1 |
| NCT Number | NCT03976375 |
Clinical Development:
Key Findings:
Wave Life Sciences has developed a stereopure ASO platform and has pursued LRRK2-targeting programs[4].
Approach:
Program Status:
Bristol Myers Squibb has ASO programs targeting LRRK2 in development[5].
| Attribute | Value |
|---|---|
| Target | LRRK2 mRNA |
| Company | Bristol Myers Squibb |
| Phase | Discovery / Preclinical |
| Indication | Parkinson's disease |
| Aspect | LRRK2 Kinase Inhibitors | LRRK2 ASOs |
|---|---|---|
| Mechanism | Enzymatic inhibition | mRNA degradation |
| Protein levels | Unchanged | Reduced |
| Dosing | Oral (small molecule) | Intrathecal (ASO) |
| Frequency | Daily | Monthly or less |
| Brain exposure | Generally good | Requires optimization |
| Reversibility | Rapid (hours) | Slow (weeks-months) |
| Off-target effects | Kinase selectivity | Off-target mRNA |
| Candidate | Company | Type | Phase |
|---|---|---|---|
| BIIB122 (DNL151) | Biogen/Denali | Kinase inhibitor | Phase 2b |
| NEU-411 | Neuron23 | Kinase inhibitor | Phase 2 |
| G007-LK | Vanqua Bio/Genentech | Kinase inhibitor | Preclinical |
| BIIB132 | Biogen/Ionis | ASO | Phase 1 |
| Wave LRRK2 ASO | Wave Life Sciences | ASO | Preclinical |
| BMS LRRK2 ASO | Bristol Myers Squibb | ASO | Discovery |
Delivery:
Safety:
Indication:
Key preclinical findings supporting LRRK2 ASO development:
Drosophila Model[1:1]:
Rodent Studies[6]:
Non-human Primate:
ASO development relies on established LRRK2 biomarkers:
| Biomarker | Matrix | Use |
|---|---|---|
| CSF LRRK2 protein | Cerebrospinal fluid | Target engagement |
| pSer935-LRRK2 | Blood PBMCs, CSF | LRRK2 kinase activity |
| pThr73-Rab10 | Blood, CSF | Downstream pathway marker |
| NfL | Plasma, CSF | Neurodegeneration |
| DAT imaging | Brain PET | Dopaminergic function |
Borel F, et al. LRRK2 antisense oligonucleotides reduce protein levels and improve phenotypes in a Drosophila model of Parkinson's disease. J Parkinsons Dis. 2018. ↩︎ ↩︎
Bennett CF, Sarnowski J. Therapeutic antisense oligonucleotides. Nat Rev Drug Discov. 2024. ↩︎
Biogen. Neurological antisense programs. 2024. ↩︎
Wave Life Sciences. LRRK2 antisense program. 2024. ↩︎
Bristol Myers Squibb Research. ASO programs in neurodegeneration. 2024. ↩︎
Torres-Yaghan R, et al. Antisense oligonucleotide therapy for LRRK2-linked Parkinson's disease. Neurobiol Dis. 2021. ↩︎